NCT02531932 - Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 16, 2015

Primary Completion Date

September 30, 2024

Study Completion Date

October 19, 2024

Conditions

Breast Cancer

Interventions

DRUG

Carboplatin

Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k

DRUG

Everolimus

The study drug Everolimus will be self-administered (by the patients themselves).

Trial Locations (3)

Mount Sinai Downtown, New York

Mount Sinai West, New York

Icahn School of Medicine at Mount Sinai, New York